Antenatal Indomethacin Treatment for Congenital Myotonic Dystrophy

Autor:	Hiroaki Tanaka, Fumi Furuhashi, Eiji Kondo, Kayo Tanaka, Kyohei Yamaguchi, Tomoaki Ikeda
Rok vydání:	2019
Předmět:	Polyhydramnios Pediatrics medicine.medical_specialty Fetus Neonatal intensive care unit Congenital Myotonic Dystrophy business.industry Obstetrics and Gynecology Case Report medicine.disease lcsh:Gynecology and obstetrics Myotonic dystrophy Optimal management Respiratory failure medicine Fetal breathing business lcsh:RG1-991
Zdroj:	Case Reports in Obstetrics and Gynecology Case Reports in Obstetrics and Gynecology, Vol 2019 (2019)
ISSN:	2090-6692 2090-6684
Popis:	Myotonic dystrophy is an autosomal-dominant disorder. Its congenital type is the most severe form, with respiratory failure that can be a life-threatening event after birth. There are no antenatal treatments that can improve neonatal outcomes of myotonic dystrophy. We treated a fetus with congenital myotonic dystrophy by administering indomethacin to the 31-year-old Japanese mother affected by myotonic dystrophy and polyhydramnios. We observed increased fetal breathing movement and a reduction of the amniotic fluid volume. The baby was born at 37 weeks and discharged from the neonatal intensive care unit with a favorable outcome. Indomethacin treatment is likely to improve fetal lung function and to control the amniotic fluid volume. This report emphasizes the importance of further investigations regarding the optimal management of congenital myotonic dystrophy.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f40b89e0a618258c410d1885ed62f816 https://doi.org/10.1155/2019/4290145 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.